Various ECD or TMD missense mutations have been associated with sensitivity to HER2-targeted inhibitors in NSCLC [7–9]; however, it is not yet a validated hallmark to predict the response to HER2-targeted agents. Here, ERBB2 is linked to non-small cell lung carcinoma.